| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 150 | 2024 | 1520 | 15.470 |
Why?
|
| Asparaginase | 36 | 2024 | 236 | 5.610 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 18 | 2023 | 407 | 2.510 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 11 | 2023 | 222 | 2.200 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 56 | 2024 | 11525 | 2.170 |
Why?
|
| Neoplasm, Residual | 16 | 2023 | 973 | 1.380 |
Why?
|
| Azacitidine | 10 | 2013 | 347 | 1.370 |
Why?
|
| Cranial Irradiation | 11 | 2016 | 401 | 1.260 |
Why?
|
| Antineoplastic Agents | 38 | 2023 | 13693 | 1.230 |
Why?
|
| Child | 152 | 2024 | 77709 | 1.110 |
Why?
|
| Child, Preschool | 101 | 2022 | 41005 | 1.100 |
Why?
|
| Myelodysplastic Syndromes | 17 | 2022 | 1352 | 1.090 |
Why?
|
| Polyethylene Glycols | 7 | 2021 | 1182 | 1.080 |
Why?
|
| Doxorubicin | 15 | 2018 | 2234 | 1.040 |
Why?
|
| Antimetabolites, Antineoplastic | 10 | 2016 | 640 | 1.020 |
Why?
|
| Infant | 83 | 2022 | 35134 | 1.010 |
Why?
|
| Osteonecrosis | 7 | 2022 | 227 | 1.000 |
Why?
|
| Dexamethasone | 12 | 2017 | 1951 | 0.980 |
Why?
|
| Ikaros Transcription Factor | 3 | 2018 | 217 | 0.850 |
Why?
|
| Leukemia | 8 | 2023 | 1510 | 0.820 |
Why?
|
| Prednisone | 11 | 2018 | 1574 | 0.810 |
Why?
|
| Philadelphia Chromosome | 6 | 2023 | 112 | 0.800 |
Why?
|
| Adolescent | 100 | 2024 | 85779 | 0.760 |
Why?
|
| Disease-Free Survival | 39 | 2023 | 6896 | 0.760 |
Why?
|
| Blood Group Antigens | 1 | 2022 | 180 | 0.740 |
Why?
|
| Remission Induction | 23 | 2022 | 2385 | 0.730 |
Why?
|
| Erwinia | 3 | 2023 | 23 | 0.690 |
Why?
|
| Down Syndrome | 3 | 2018 | 880 | 0.660 |
Why?
|
| Cardiotoxins | 2 | 2013 | 41 | 0.570 |
Why?
|
| Gene Expression Regulation, Leukemic | 11 | 2021 | 651 | 0.550 |
Why?
|
| Sequence Deletion | 4 | 2018 | 1525 | 0.540 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2018 | 639 | 0.540 |
Why?
|
| Pancreatitis | 4 | 2023 | 1092 | 0.530 |
Why?
|
| Prognosis | 42 | 2022 | 29060 | 0.530 |
Why?
|
| Survival Rate | 25 | 2021 | 12788 | 0.510 |
Why?
|
| Razoxane | 6 | 2012 | 44 | 0.510 |
Why?
|
| Gene Fusion | 1 | 2018 | 371 | 0.500 |
Why?
|
| Venous Thromboembolism | 2 | 2022 | 1671 | 0.500 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 14 | 2022 | 5445 | 0.490 |
Why?
|
| Drug Hypersensitivity | 6 | 2023 | 884 | 0.490 |
Why?
|
| Bacteremia | 2 | 2018 | 963 | 0.480 |
Why?
|
| Humans | 231 | 2024 | 744366 | 0.480 |
Why?
|
| Immunotoxins | 3 | 2020 | 179 | 0.470 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2021 | 9240 | 0.460 |
Why?
|
| Leukemia, B-Cell | 4 | 2015 | 86 | 0.450 |
Why?
|
| Vincristine | 6 | 2018 | 1039 | 0.440 |
Why?
|
| Methotrexate | 12 | 2018 | 1728 | 0.440 |
Why?
|
| Male | 130 | 2023 | 350115 | 0.430 |
Why?
|
| Hemochromatosis | 1 | 2013 | 184 | 0.410 |
Why?
|
| Female | 129 | 2023 | 380193 | 0.410 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 10 | 2019 | 294 | 0.410 |
Why?
|
| Escherichia coli | 6 | 2023 | 4217 | 0.400 |
Why?
|
| Antineoplastic Agents, Hormonal | 4 | 2013 | 1524 | 0.400 |
Why?
|
| Antibiotics, Antineoplastic | 6 | 2016 | 692 | 0.400 |
Why?
|
| Blood Transfusion | 2 | 2009 | 1301 | 0.400 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 2020 | 841 | 0.370 |
Why?
|
| Leukemia, Myeloid, Acute | 13 | 2017 | 3524 | 0.370 |
Why?
|
| Leukocyte Count | 9 | 2018 | 1588 | 0.360 |
Why?
|
| Histone-Lysine N-Methyltransferase | 11 | 2019 | 670 | 0.350 |
Why?
|
| Proto-Oncogenes | 5 | 2003 | 321 | 0.350 |
Why?
|
| Recurrence | 21 | 2022 | 8340 | 0.350 |
Why?
|
| Treatment Outcome | 46 | 2023 | 63107 | 0.350 |
Why?
|
| Blast Crisis | 1 | 2009 | 103 | 0.350 |
Why?
|
| Drug Resistance, Neoplasm | 12 | 2021 | 5172 | 0.340 |
Why?
|
| Translocation, Genetic | 10 | 2023 | 1420 | 0.340 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2018 | 5534 | 0.340 |
Why?
|
| Chromosome Aberrations | 8 | 2012 | 1813 | 0.340 |
Why?
|
| Exotoxins | 2 | 2020 | 119 | 0.330 |
Why?
|
| Escherichia coli Proteins | 1 | 2015 | 1050 | 0.330 |
Why?
|
| Proto-Oncogene Proteins | 10 | 2019 | 4554 | 0.320 |
Why?
|
| Follow-Up Studies | 24 | 2021 | 39052 | 0.320 |
Why?
|
| Etoposide | 6 | 2022 | 641 | 0.310 |
Why?
|
| Thrombosis | 1 | 2022 | 2968 | 0.310 |
Why?
|
| Cognition | 5 | 2016 | 6770 | 0.300 |
Why?
|
| Oncogene Proteins, Fusion | 9 | 2023 | 1581 | 0.290 |
Why?
|
| Cardiotonic Agents | 5 | 2016 | 535 | 0.290 |
Why?
|
| Young Adult | 27 | 2024 | 56429 | 0.290 |
Why?
|
| Hematologic Neoplasms | 4 | 2023 | 1832 | 0.280 |
Why?
|
| Neoplasm Proteins | 9 | 2019 | 3707 | 0.280 |
Why?
|
| Neoplasms, Second Primary | 4 | 2020 | 1062 | 0.280 |
Why?
|
| Survivors | 7 | 2016 | 2291 | 0.270 |
Why?
|
| Cell Transformation, Neoplastic | 6 | 2018 | 2943 | 0.260 |
Why?
|
| Gene Rearrangement | 11 | 2022 | 1179 | 0.260 |
Why?
|
| Maximum Tolerated Dose | 4 | 2018 | 892 | 0.260 |
Why?
|
| Immunophenotyping | 10 | 2018 | 1880 | 0.260 |
Why?
|
| Age Factors | 16 | 2020 | 18373 | 0.260 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 4 | 2008 | 166 | 0.260 |
Why?
|
| Immunotherapy | 2 | 2017 | 4446 | 0.250 |
Why?
|
| Combined Modality Therapy | 13 | 2020 | 8642 | 0.250 |
Why?
|
| Polymorphism, Genetic | 5 | 2019 | 4328 | 0.250 |
Why?
|
| Arabinonucleosides | 3 | 2022 | 35 | 0.240 |
Why?
|
| Multicenter Studies as Topic | 5 | 2022 | 1677 | 0.240 |
Why?
|
| Treatment Failure | 6 | 2022 | 2618 | 0.240 |
Why?
|
| Calcification, Physiologic | 1 | 2004 | 169 | 0.240 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2014 | 1157 | 0.240 |
Why?
|
| Heart Diseases | 2 | 2015 | 2789 | 0.230 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2007 | 895 | 0.230 |
Why?
|
| Capillary Leak Syndrome | 2 | 2020 | 31 | 0.230 |
Why?
|
| Gels | 1 | 2004 | 427 | 0.230 |
Why?
|
| BRCA2 Protein | 2 | 2019 | 794 | 0.220 |
Why?
|
| Bacterial Toxins | 2 | 2020 | 931 | 0.220 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2018 | 6539 | 0.220 |
Why?
|
| Central Nervous System Diseases | 1 | 2007 | 518 | 0.220 |
Why?
|
| Cyclophosphamide | 5 | 2022 | 2242 | 0.220 |
Why?
|
| Mutation | 16 | 2022 | 29786 | 0.220 |
Why?
|
| Oncogene Protein pp60(v-src) | 2 | 1992 | 77 | 0.220 |
Why?
|
| Clinical Protocols | 3 | 2011 | 1461 | 0.220 |
Why?
|
| Glucocorticoids | 5 | 2022 | 2108 | 0.210 |
Why?
|
| Bone Marrow Cells | 2 | 2009 | 2513 | 0.210 |
Why?
|
| Survival Analysis | 13 | 2021 | 10252 | 0.210 |
Why?
|
| Infant, Newborn | 21 | 2019 | 25628 | 0.210 |
Why?
|
| Receptors, Antigen, T-Cell | 5 | 2019 | 2540 | 0.210 |
Why?
|
| Medical Oncology | 3 | 2020 | 2267 | 0.210 |
Why?
|
| Aminopyridines | 2 | 2016 | 542 | 0.210 |
Why?
|
| Cytogenetics | 3 | 2016 | 203 | 0.210 |
Why?
|
| Neoplastic Stem Cells | 5 | 2021 | 1376 | 0.210 |
Why?
|
| Stem Cell Transplantation | 4 | 2016 | 1620 | 0.210 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2020 | 9955 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 11 | 4 | 2022 | 417 | 0.210 |
Why?
|
| Transcription Factors | 8 | 2023 | 12207 | 0.200 |
Why?
|
| Poverty | 2 | 2024 | 2660 | 0.200 |
Why?
|
| Risk Assessment | 8 | 2021 | 23336 | 0.200 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 6 | 2015 | 345 | 0.200 |
Why?
|
| Cytarabine | 7 | 2019 | 692 | 0.200 |
Why?
|
| Apoptosis | 8 | 2022 | 9724 | 0.200 |
Why?
|
| Lymphoma | 2 | 2023 | 1877 | 0.190 |
Why?
|
| Risk Factors | 26 | 2023 | 72296 | 0.190 |
Why?
|
| Drug Administration Schedule | 8 | 2014 | 4933 | 0.190 |
Why?
|
| Adenine Nucleotides | 2 | 2011 | 121 | 0.190 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2022 | 2110 | 0.180 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2021 | 3554 | 0.180 |
Why?
|
| Hypertriglyceridemia | 1 | 2023 | 293 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 21 | 3 | 2015 | 230 | 0.180 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2022 | 172 | 0.180 |
Why?
|
| Diploidy | 2 | 2019 | 138 | 0.180 |
Why?
|
| Gene Duplication | 2 | 2014 | 329 | 0.180 |
Why?
|
| Hodgkin Disease | 1 | 2008 | 1415 | 0.180 |
Why?
|
| Adult | 42 | 2023 | 214052 | 0.180 |
Why?
|
| Epigenesis, Genetic | 5 | 2015 | 3646 | 0.180 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 7182 | 0.180 |
Why?
|
| Chemokine CXCL2 | 1 | 2019 | 115 | 0.180 |
Why?
|
| Duffy Blood-Group System | 1 | 2019 | 58 | 0.170 |
Why?
|
| Fractures, Spontaneous | 1 | 2001 | 230 | 0.170 |
Why?
|
| Parents | 4 | 2023 | 3405 | 0.170 |
Why?
|
| Fanconi Anemia Complementation Group D2 Protein | 1 | 2019 | 148 | 0.170 |
Why?
|
| Trypsinogen | 1 | 2018 | 86 | 0.170 |
Why?
|
| Leukemia, Biphenotypic, Acute | 1 | 2018 | 35 | 0.160 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2019 | 15520 | 0.160 |
Why?
|
| T-Lymphocytes | 11 | 2023 | 10183 | 0.160 |
Why?
|
| Bacillus | 1 | 2018 | 77 | 0.160 |
Why?
|
| Membrane Proteins | 5 | 2019 | 7882 | 0.160 |
Why?
|
| Galectins | 1 | 2021 | 268 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2014 | 988 | 0.160 |
Why?
|
| Neoplasms | 8 | 2023 | 21696 | 0.160 |
Why?
|
| Neuropsychological Tests | 6 | 2023 | 6994 | 0.160 |
Why?
|
| Nutrition Disorders | 1 | 2019 | 211 | 0.160 |
Why?
|
| Trypsin | 1 | 2018 | 511 | 0.160 |
Why?
|
| HMGB Proteins | 1 | 2017 | 45 | 0.150 |
Why?
|
| Health Status | 3 | 2021 | 4034 | 0.150 |
Why?
|
| Adenoviruses, Human | 2 | 1989 | 257 | 0.150 |
Why?
|
| Quality of Life | 5 | 2023 | 12802 | 0.150 |
Why?
|
| Radiation Tolerance | 2 | 2019 | 486 | 0.150 |
Why?
|
| Immune Evasion | 1 | 2021 | 360 | 0.150 |
Why?
|
| Lymphoma, T-Cell | 1 | 2020 | 299 | 0.150 |
Why?
|
| Aspartate-Ammonia Ligase | 2 | 2014 | 16 | 0.150 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2019 | 473 | 0.150 |
Why?
|
| Antigens, CD19 | 1 | 2019 | 380 | 0.150 |
Why?
|
| Capsid | 2 | 1989 | 437 | 0.150 |
Why?
|
| Thymidylate Synthase | 1 | 2016 | 75 | 0.150 |
Why?
|
| Pharmacogenetics | 4 | 2015 | 674 | 0.140 |
Why?
|
| Leukemia, Myeloid | 4 | 2004 | 707 | 0.140 |
Why?
|
| Infusions, Intravenous | 4 | 2012 | 2274 | 0.140 |
Why?
|
| Lysine | 4 | 2014 | 1007 | 0.140 |
Why?
|
| Time Factors | 15 | 2019 | 40075 | 0.140 |
Why?
|
| Myristic Acids | 2 | 1993 | 48 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2022 | 1434 | 0.140 |
Why?
|
| Capsid Proteins | 2 | 1989 | 479 | 0.140 |
Why?
|
| Cognition Disorders | 4 | 2016 | 4043 | 0.140 |
Why?
|
| Executive Function | 2 | 2023 | 1364 | 0.140 |
Why?
|
| Injections, Subcutaneous | 4 | 2006 | 667 | 0.140 |
Why?
|
| HIV Seropositivity | 1 | 2002 | 971 | 0.140 |
Why?
|
| Cataract | 1 | 2022 | 834 | 0.130 |
Why?
|
| Retrospective Studies | 23 | 2023 | 77460 | 0.130 |
Why?
|
| Troponin T | 3 | 2012 | 754 | 0.130 |
Why?
|
| Tissue Banks | 1 | 2016 | 184 | 0.130 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2015 | 107 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 6 | 2016 | 6171 | 0.130 |
Why?
|
| Fusion Proteins, bcr-abl | 4 | 2014 | 434 | 0.130 |
Why?
|
| Multivariate Analysis | 5 | 2018 | 12244 | 0.130 |
Why?
|
| Health Status Disparities | 2 | 2024 | 1796 | 0.130 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2022 | 1381 | 0.130 |
Why?
|
| Fractures, Bone | 3 | 2017 | 1947 | 0.130 |
Why?
|
| Proportional Hazards Models | 10 | 2022 | 12356 | 0.130 |
Why?
|
| Medication Adherence | 2 | 2016 | 2063 | 0.130 |
Why?
|
| Burkitt Lymphoma | 3 | 2007 | 327 | 0.130 |
Why?
|
| Genotype | 8 | 2018 | 12952 | 0.130 |
Why?
|
| Haploinsufficiency | 2 | 2019 | 328 | 0.130 |
Why?
|
| Brain Abscess | 1 | 2015 | 118 | 0.120 |
Why?
|
| Cardiomyopathies | 4 | 2012 | 1912 | 0.120 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 2 | 2005 | 111 | 0.120 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 426 | 0.120 |
Why?
|
| HMGN1 Protein | 1 | 2014 | 27 | 0.120 |
Why?
|
| Feasibility Studies | 4 | 2023 | 5077 | 0.120 |
Why?
|
| Injections, Intramuscular | 1 | 2015 | 552 | 0.120 |
Why?
|
| Receptors, Cell Surface | 2 | 2019 | 2865 | 0.120 |
Why?
|
| DNA, Intergenic | 1 | 2014 | 107 | 0.120 |
Why?
|
| Mitochondria, Heart | 1 | 2016 | 247 | 0.120 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2002 | 1100 | 0.120 |
Why?
|
| Gram-Positive Bacterial Infections | 2 | 2015 | 341 | 0.120 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2017 | 3390 | 0.120 |
Why?
|
| Injections, Spinal | 3 | 2016 | 303 | 0.120 |
Why?
|
| Hypersensitivity | 1 | 2023 | 1102 | 0.120 |
Why?
|
| Wilms Tumor | 1 | 2016 | 373 | 0.120 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 1178 | 0.120 |
Why?
|
| Genes, src | 1 | 1993 | 52 | 0.120 |
Why?
|
| Biological Products | 1 | 2022 | 860 | 0.110 |
Why?
|
| Neutropenia | 1 | 2018 | 895 | 0.110 |
Why?
|
| INDEL Mutation | 1 | 2014 | 279 | 0.110 |
Why?
|
| Histones | 3 | 2014 | 2598 | 0.110 |
Why?
|
| Antigens, CD34 | 1 | 2015 | 659 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2016 | 539 | 0.110 |
Why?
|
| Purines | 1 | 2016 | 594 | 0.110 |
Why?
|
| Genomic Instability | 1 | 2017 | 695 | 0.110 |
Why?
|
| Hedgehog Proteins | 1 | 2018 | 783 | 0.110 |
Why?
|
| Incidence | 10 | 2022 | 20952 | 0.110 |
Why?
|
| Protein Kinases | 2 | 2018 | 1640 | 0.110 |
Why?
|
| Cell Membrane | 2 | 1993 | 3749 | 0.110 |
Why?
|
| Nutritional Status | 2 | 2019 | 1609 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2014 | 2504 | 0.110 |
Why?
|
| Karyotyping | 5 | 2014 | 1243 | 0.110 |
Why?
|
| Gene Deletion | 2 | 2011 | 2751 | 0.110 |
Why?
|
| Hyperglycemia | 1 | 2021 | 1373 | 0.110 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 4 | 2004 | 1660 | 0.110 |
Why?
|
| Orthopedics | 1 | 2022 | 904 | 0.110 |
Why?
|
| bcl-X Protein | 1 | 2014 | 411 | 0.110 |
Why?
|
| Pyrroles | 3 | 2004 | 1146 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myb | 2 | 2014 | 78 | 0.110 |
Why?
|
| Cell Proliferation | 5 | 2017 | 10483 | 0.110 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2016 | 604 | 0.110 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2015 | 689 | 0.110 |
Why?
|
| Anthracyclines | 1 | 2014 | 288 | 0.110 |
Why?
|
| Echocardiography | 4 | 2013 | 5099 | 0.110 |
Why?
|
| Canada | 2 | 2015 | 2065 | 0.110 |
Why?
|
| Transplantation, Homologous | 3 | 2020 | 4777 | 0.110 |
Why?
|
| Multigene Family | 2 | 2010 | 1102 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2010 | 658 | 0.100 |
Why?
|
| Pediatrics | 2 | 2019 | 3475 | 0.100 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2015 | 789 | 0.100 |
Why?
|
| Anticoagulants | 2 | 2022 | 4600 | 0.100 |
Why?
|
| Janus Kinase 2 | 1 | 2015 | 528 | 0.100 |
Why?
|
| Antioxidants | 1 | 2020 | 1659 | 0.100 |
Why?
|
| Activating Transcription Factors | 1 | 2011 | 29 | 0.100 |
Why?
|
| Nutrition Surveys | 1 | 2019 | 1660 | 0.100 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2010 | 496 | 0.100 |
Why?
|
| Protein Sorting Signals | 1 | 1992 | 281 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2012 | 322 | 0.100 |
Why?
|
| RNA Splicing | 2 | 2022 | 908 | 0.100 |
Why?
|
| Drugs, Investigational | 1 | 2013 | 214 | 0.100 |
Why?
|
| Cell Line, Tumor | 10 | 2019 | 16690 | 0.100 |
Why?
|
| Salvage Therapy | 4 | 2019 | 1275 | 0.100 |
Why?
|
| Cardiovascular Agents | 2 | 2010 | 850 | 0.100 |
Why?
|
| Myeloproliferative Disorders | 2 | 2010 | 606 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2018 | 10943 | 0.100 |
Why?
|
| Genes, T-Cell Receptor gamma | 1 | 2010 | 16 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2020 | 3595 | 0.100 |
Why?
|
| Indoles | 3 | 2004 | 1839 | 0.090 |
Why?
|
| Cohort Studies | 14 | 2021 | 40559 | 0.090 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 2182 | 0.090 |
Why?
|
| DNA, Mitochondrial | 1 | 2016 | 817 | 0.090 |
Why?
|
| Methylation | 2 | 2014 | 1106 | 0.090 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2010 | 64 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2017 | 3773 | 0.090 |
Why?
|
| Benzimidazoles | 1 | 2015 | 850 | 0.090 |
Why?
|
| Prospective Studies | 13 | 2023 | 53290 | 0.090 |
Why?
|
| Peptide Fragments | 5 | 2014 | 5096 | 0.090 |
Why?
|
| Codon, Terminator | 1 | 2010 | 127 | 0.090 |
Why?
|
| Genetic Counseling | 1 | 2013 | 600 | 0.090 |
Why?
|
| RNA, Messenger | 6 | 2013 | 13035 | 0.090 |
Why?
|
| Sweet Syndrome | 1 | 2009 | 47 | 0.090 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 950 | 0.090 |
Why?
|
| Genetic Variation | 2 | 2018 | 6542 | 0.090 |
Why?
|
| Antigens, CD | 5 | 2018 | 4026 | 0.090 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 1 | 2009 | 143 | 0.090 |
Why?
|
| Ventricular Function, Left | 5 | 2015 | 3666 | 0.080 |
Why?
|
| Histone Demethylases | 1 | 2012 | 321 | 0.080 |
Why?
|
| Diet | 2 | 2019 | 7937 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2022 | 2938 | 0.080 |
Why?
|
| International Agencies | 1 | 2009 | 240 | 0.080 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 1837 | 0.080 |
Why?
|
| International Cooperation | 1 | 2015 | 1420 | 0.080 |
Why?
|
| Topotecan | 1 | 2009 | 137 | 0.080 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2014 | 1115 | 0.080 |
Why?
|
| Microfilament Proteins | 1 | 2014 | 1152 | 0.080 |
Why?
|
| Bone Marrow | 6 | 2016 | 2948 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 4 | 2004 | 2455 | 0.080 |
Why?
|
| DNA-Binding Proteins | 6 | 2023 | 9647 | 0.080 |
Why?
|
| Sialoglycoproteins | 1 | 1989 | 318 | 0.080 |
Why?
|
| Nuclear Proteins | 2 | 2014 | 5856 | 0.080 |
Why?
|
| Energy Intake | 1 | 2016 | 2148 | 0.080 |
Why?
|
| STAT3 Transcription Factor | 1 | 2012 | 874 | 0.080 |
Why?
|
| Alleles | 6 | 2018 | 6933 | 0.080 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2014 | 1340 | 0.080 |
Why?
|
| Behavior | 1 | 2011 | 561 | 0.080 |
Why?
|
| Protein Processing, Post-Translational | 2 | 1993 | 1988 | 0.080 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 2 | 2007 | 113 | 0.080 |
Why?
|
| Clinical Trials as Topic | 6 | 2019 | 7914 | 0.080 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2019 | 1856 | 0.080 |
Why?
|
| Receptor, Notch1 | 2 | 2008 | 502 | 0.070 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 1989 | 442 | 0.070 |
Why?
|
| Alu Elements | 1 | 2007 | 119 | 0.070 |
Why?
|
| Middle Aged | 25 | 2022 | 213390 | 0.070 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1941 | 0.070 |
Why?
|
| Regression Analysis | 2 | 2011 | 6459 | 0.070 |
Why?
|
| Gene Silencing | 2 | 2014 | 1539 | 0.070 |
Why?
|
| Sulfonamides | 2 | 2014 | 1940 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 4 | 2014 | 2765 | 0.070 |
Why?
|
| B-Lymphocytes | 5 | 2014 | 4666 | 0.070 |
Why?
|
| Ploidies | 1 | 2007 | 281 | 0.070 |
Why?
|
| Disease Progression | 4 | 2021 | 13286 | 0.070 |
Why?
|
| United States | 8 | 2021 | 69872 | 0.070 |
Why?
|
| RNA, Small Interfering | 2 | 2014 | 3505 | 0.070 |
Why?
|
| Age Distribution | 2 | 2011 | 2902 | 0.070 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 5 | 2016 | 491 | 0.070 |
Why?
|
| Exons | 3 | 2023 | 2439 | 0.070 |
Why?
|
| Actins | 1 | 2014 | 2121 | 0.070 |
Why?
|
| Animals | 22 | 2023 | 168768 | 0.070 |
Why?
|
| Antigens, Differentiation | 1 | 1989 | 927 | 0.070 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2008 | 171 | 0.070 |
Why?
|
| Acute Disease | 7 | 2022 | 7147 | 0.070 |
Why?
|
| Mice | 14 | 2023 | 81201 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2016 | 2265 | 0.070 |
Why?
|
| Gene Frequency | 3 | 2017 | 3587 | 0.070 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 1364 | 0.070 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2017 | 1736 | 0.070 |
Why?
|
| Base Sequence | 6 | 2014 | 12797 | 0.070 |
Why?
|
| Neoplasm Staging | 4 | 2013 | 11031 | 0.070 |
Why?
|
| Cytogenetic Analysis | 3 | 2015 | 295 | 0.060 |
Why?
|
| Heart | 2 | 2012 | 4464 | 0.060 |
Why?
|
| Disease Management | 1 | 2016 | 2460 | 0.060 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 1739 | 0.060 |
Why?
|
| Administration, Oral | 3 | 2022 | 3914 | 0.060 |
Why?
|
| Consensus | 3 | 2022 | 2960 | 0.060 |
Why?
|
| Agar | 1 | 2004 | 56 | 0.060 |
Why?
|
| Chemical Precipitation | 1 | 2004 | 179 | 0.060 |
Why?
|
| Flow Cytometry | 5 | 2018 | 5974 | 0.060 |
Why?
|
| HLA Antigens | 1 | 2010 | 1382 | 0.060 |
Why?
|
| Phenotype | 7 | 2018 | 16367 | 0.060 |
Why?
|
| Genes, Immunoglobulin | 1 | 2005 | 291 | 0.060 |
Why?
|
| Gene Expression | 6 | 2016 | 7798 | 0.060 |
Why?
|
| Sepharose | 1 | 2004 | 108 | 0.060 |
Why?
|
| Signal Transduction | 7 | 2018 | 23404 | 0.060 |
Why?
|
| Immunoglobulin Joining Region | 1 | 2004 | 36 | 0.060 |
Why?
|
| Haplotypes | 3 | 2019 | 2779 | 0.060 |
Why?
|
| Cell-Free System | 1 | 2004 | 344 | 0.060 |
Why?
|
| Mutation, Missense | 2 | 2011 | 2566 | 0.060 |
Why?
|
| Molecular Sequence Data | 6 | 2014 | 18111 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2015 | 3084 | 0.060 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 2003 | 40 | 0.060 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2012 | 1572 | 0.060 |
Why?
|
| Benzamides | 1 | 2009 | 1379 | 0.060 |
Why?
|
| Durapatite | 1 | 2004 | 161 | 0.060 |
Why?
|
| Genome-Wide Association Study | 3 | 2019 | 12262 | 0.060 |
Why?
|
| Chromatin | 1 | 2015 | 2933 | 0.060 |
Why?
|
| Sequence Analysis, RNA | 2 | 2023 | 2012 | 0.060 |
Why?
|
| Myristic Acid | 2 | 1993 | 47 | 0.060 |
Why?
|
| Mitochondria | 2 | 2018 | 3514 | 0.060 |
Why?
|
| Fatal Outcome | 3 | 2020 | 1851 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 3 | 2021 | 2725 | 0.060 |
Why?
|
| Mice, Inbred NOD | 2 | 2019 | 1879 | 0.060 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2009 | 1142 | 0.060 |
Why?
|
| Daunorubicin | 2 | 2019 | 158 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 5749 | 0.060 |
Why?
|
| Plant Nectar | 1 | 2022 | 3 | 0.060 |
Why?
|
| Arvicolinae | 2 | 1992 | 22 | 0.060 |
Why?
|
| Leukemia, T-Cell | 1 | 2003 | 104 | 0.050 |
Why?
|
| Gelatin | 1 | 2004 | 225 | 0.050 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2004 | 421 | 0.050 |
Why?
|
| Retinoids | 1 | 2023 | 101 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2023 | 318 | 0.050 |
Why?
|
| Diffusion | 1 | 2004 | 832 | 0.050 |
Why?
|
| Trisomy | 2 | 1995 | 266 | 0.050 |
Why?
|
| Neoplasm Transplantation | 2 | 2017 | 2086 | 0.050 |
Why?
|
| Genetic Association Studies | 3 | 2018 | 2703 | 0.050 |
Why?
|
| Analysis of Variance | 3 | 2016 | 6366 | 0.050 |
Why?
|
| Janus Kinase 3 | 1 | 2022 | 78 | 0.050 |
Why?
|
| Systems Analysis | 1 | 2023 | 172 | 0.050 |
Why?
|
| Risk | 2 | 2011 | 9688 | 0.050 |
Why?
|
| Protein Biosynthesis | 1 | 1989 | 2126 | 0.050 |
Why?
|
| Nucleosides | 1 | 2022 | 138 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2013 | 4751 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 7785 | 0.050 |
Why?
|
| Staurosporine | 1 | 2003 | 251 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2014 | 8432 | 0.050 |
Why?
|
| Drug Synergism | 2 | 2016 | 1794 | 0.050 |
Why?
|
| Home Nursing | 1 | 2002 | 92 | 0.050 |
Why?
|
| Skin Tests | 1 | 2003 | 613 | 0.050 |
Why?
|
| Lymphocyte Activation | 2 | 1989 | 5524 | 0.050 |
Why?
|
| Chromogranins | 1 | 2022 | 160 | 0.050 |
Why?
|
| Electromagnetic Fields | 1 | 2003 | 298 | 0.050 |
Why?
|
| Blood Cell Count | 1 | 2002 | 403 | 0.050 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2004 | 659 | 0.050 |
Why?
|
| Aged | 16 | 2023 | 163288 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 2850 | 0.050 |
Why?
|
| Zebrafish | 3 | 2018 | 2996 | 0.050 |
Why?
|
| Phosphates | 1 | 2004 | 785 | 0.050 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2004 | 524 | 0.050 |
Why?
|
| Pons | 1 | 2022 | 245 | 0.050 |
Why?
|
| Cross-Over Studies | 2 | 2005 | 2029 | 0.050 |
Why?
|
| Oncogenes | 2 | 2018 | 1265 | 0.050 |
Why?
|
| Quebec | 1 | 2020 | 134 | 0.050 |
Why?
|
| Heart Ventricles | 1 | 2012 | 3817 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2003 | 547 | 0.050 |
Why?
|
| Bacterial Proteins | 1 | 2014 | 3854 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2011 | 3024 | 0.050 |
Why?
|
| Recombinant Proteins | 3 | 2016 | 6621 | 0.050 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2022 | 199 | 0.050 |
Why?
|
| Alanine Transaminase | 1 | 2022 | 592 | 0.040 |
Why?
|
| Kidney Neoplasms | 1 | 2016 | 4262 | 0.040 |
Why?
|
| Vitamin A | 1 | 2023 | 615 | 0.040 |
Why?
|
| Hydrocortisone | 1 | 2007 | 1826 | 0.040 |
Why?
|
| Memory Disorders | 2 | 2004 | 1186 | 0.040 |
Why?
|
| Organizations, Nonprofit | 1 | 2020 | 104 | 0.040 |
Why?
|
| Mitoxantrone | 1 | 2019 | 152 | 0.040 |
Why?
|
| DNA Damage | 1 | 2009 | 2432 | 0.040 |
Why?
|
| DNA Mutational Analysis | 3 | 2017 | 4185 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 647 | 0.040 |
Why?
|
| Fatigue | 2 | 2023 | 1531 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2006 | 6489 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2019 | 17446 | 0.040 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2021 | 434 | 0.040 |
Why?
|
| Internship and Residency | 1 | 2019 | 5791 | 0.040 |
Why?
|
| Methylprednisolone | 1 | 2000 | 387 | 0.040 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2004 | 570 | 0.040 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 1992 | 906 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2005 | 1348 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2023 | 1730 | 0.040 |
Why?
|
| Models, Biological | 4 | 2018 | 9584 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2023 | 8319 | 0.040 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 2 | 1995 | 17 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 3 | 2019 | 4805 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2020 | 343 | 0.040 |
Why?
|
| Aged, 80 and over | 7 | 2009 | 57776 | 0.040 |
Why?
|
| Jurkat Cells | 1 | 2019 | 743 | 0.040 |
Why?
|
| Cell Lineage | 3 | 2016 | 2504 | 0.040 |
Why?
|
| Gene Expression Profiling | 4 | 2022 | 9445 | 0.040 |
Why?
|
| Myocardial Contraction | 2 | 2015 | 1579 | 0.040 |
Why?
|
| Germ Cells | 1 | 2021 | 631 | 0.040 |
Why?
|
| Calcium | 4 | 2004 | 5755 | 0.040 |
Why?
|
| Pyridines | 1 | 2009 | 2825 | 0.040 |
Why?
|
| Cancer Vaccines | 1 | 2005 | 1023 | 0.040 |
Why?
|
| Research Design | 3 | 2021 | 5984 | 0.040 |
Why?
|
| Drug Monitoring | 2 | 2016 | 956 | 0.040 |
Why?
|
| Leukemic Infiltration | 1 | 1997 | 48 | 0.040 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 2017 | 110 | 0.040 |
Why?
|
| Internet | 2 | 2016 | 3056 | 0.040 |
Why?
|
| Radiation Injuries | 1 | 2004 | 1180 | 0.040 |
Why?
|
| Cells, Cultured | 4 | 2015 | 19233 | 0.040 |
Why?
|
| Clone Cells | 2 | 2003 | 1692 | 0.040 |
Why?
|
| Body Height | 1 | 2003 | 1578 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2004 | 1741 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2021 | 6313 | 0.040 |
Why?
|
| Hypoalbuminemia | 1 | 2017 | 85 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 2022 | 1117 | 0.040 |
Why?
|
| Anaphylaxis | 1 | 2003 | 746 | 0.030 |
Why?
|
| Memory, Short-Term | 1 | 2023 | 977 | 0.030 |
Why?
|
| Genes, BRCA2 | 1 | 2019 | 618 | 0.030 |
Why?
|
| Protein Binding | 3 | 1993 | 9384 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2005 | 1271 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2019 | 1723 | 0.030 |
Why?
|
| Chromatography, Thin Layer | 1 | 2016 | 223 | 0.030 |
Why?
|
| Nurse-Patient Relations | 1 | 2016 | 101 | 0.030 |
Why?
|
| Drug Dosage Calculations | 1 | 2016 | 114 | 0.030 |
Why?
|
| Boston | 2 | 2016 | 9312 | 0.030 |
Why?
|
| Bacillus cereus | 1 | 2015 | 35 | 0.030 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2019 | 290 | 0.030 |
Why?
|
| Leukemia, Experimental | 1 | 2016 | 246 | 0.030 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2017 | 132 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 2019 | 781 | 0.030 |
Why?
|
| Electron Transport Complex IV | 1 | 2016 | 189 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2002 | 2560 | 0.030 |
Why?
|
| DNA | 1 | 2009 | 7294 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2018 | 497 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2002 | 1904 | 0.030 |
Why?
|
| Meninges | 1 | 1997 | 190 | 0.030 |
Why?
|
| Sirolimus | 1 | 2022 | 1565 | 0.030 |
Why?
|
| Genomics | 2 | 2023 | 5717 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2021 | 1157 | 0.030 |
Why?
|
| Binding Sites | 2 | 2014 | 6111 | 0.030 |
Why?
|
| Benzothiazoles | 1 | 2016 | 248 | 0.030 |
Why?
|
| Electron Transport Complex I | 1 | 2016 | 140 | 0.030 |
Why?
|
| Counseling | 1 | 2023 | 1523 | 0.030 |
Why?
|
| Secondary Prevention | 2 | 2016 | 1530 | 0.030 |
Why?
|
| Cytoprotection | 1 | 2015 | 210 | 0.030 |
Why?
|
| Morbidity | 1 | 2020 | 1768 | 0.030 |
Why?
|
| Ultraviolet Rays | 1 | 2019 | 1060 | 0.030 |
Why?
|
| SEER Program | 1 | 2020 | 1507 | 0.030 |
Why?
|
| Isoquinolines | 1 | 2016 | 366 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2002 | 20824 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2010 | 3921 | 0.030 |
Why?
|
| Chromosome Deletion | 2 | 2004 | 1401 | 0.030 |
Why?
|
| Fanconi Anemia | 1 | 2016 | 319 | 0.030 |
Why?
|
| Amino Acid Sequence | 3 | 2004 | 13814 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2023 | 2682 | 0.030 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2014 | 115 | 0.030 |
Why?
|
| Alkylation | 1 | 1993 | 86 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2016 | 755 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 381 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2022 | 2441 | 0.030 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 25039 | 0.030 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 3611 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2016 | 281 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2016 | 779 | 0.030 |
Why?
|
| Transcription, Genetic | 3 | 2018 | 7721 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2002 | 1580 | 0.030 |
Why?
|
| Cyclosporine | 1 | 1996 | 788 | 0.030 |
Why?
|
| Consensus Sequence | 1 | 1993 | 378 | 0.030 |
Why?
|
| Phenylurea Compounds | 1 | 2016 | 528 | 0.030 |
Why?
|
| Metabolomics | 1 | 2021 | 1485 | 0.030 |
Why?
|
| Animals, Genetically Modified | 1 | 2017 | 1549 | 0.030 |
Why?
|
| Valproic Acid | 1 | 2015 | 445 | 0.030 |
Why?
|
| Body Weight | 1 | 2003 | 4671 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2005 | 4386 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 1997 | 1758 | 0.030 |
Why?
|
| Overweight | 1 | 2023 | 2371 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2014 | 475 | 0.030 |
Why?
|
| Chromosome Disorders | 1 | 1995 | 514 | 0.030 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2014 | 798 | 0.030 |
Why?
|
| Nucleoside Transport Proteins | 1 | 2011 | 8 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 1989 | 9274 | 0.030 |
Why?
|
| Cell Compartmentation | 1 | 1992 | 402 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 1993 | 1157 | 0.030 |
Why?
|
| RNA | 1 | 2022 | 2749 | 0.030 |
Why?
|
| Acetylation | 1 | 2014 | 1084 | 0.030 |
Why?
|
| Subcellular Fractions | 1 | 1992 | 547 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2017 | 9849 | 0.030 |
Why?
|
| Phosphorylation | 3 | 2016 | 8436 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2005 | 4479 | 0.020 |
Why?
|
| Phosphatidylinositols | 2 | 1989 | 291 | 0.020 |
Why?
|
| Random Allocation | 1 | 2016 | 2428 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 1788 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 1992 | 898 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 1992 | 403 | 0.020 |
Why?
|
| Homeodomain Proteins | 3 | 2008 | 2418 | 0.020 |
Why?
|
| Health Literacy | 1 | 2016 | 414 | 0.020 |
Why?
|
| Denmark | 1 | 2013 | 738 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2015 | 1063 | 0.020 |
Why?
|
| Homozygote | 1 | 2015 | 1787 | 0.020 |
Why?
|
| Genetic Testing | 3 | 2015 | 3444 | 0.020 |
Why?
|
| Linear Models | 2 | 2016 | 5953 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2011 | 297 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 2 | 2014 | 5867 | 0.020 |
Why?
|
| Nucleosomes | 1 | 2014 | 494 | 0.020 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 725 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2016 | 2184 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2015 | 847 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1995 | 689 | 0.020 |
Why?
|
| Lipids | 1 | 2021 | 3307 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2012 | 402 | 0.020 |
Why?
|
| Polyribosomes | 1 | 1989 | 110 | 0.020 |
Why?
|
| Ionophores | 1 | 1989 | 108 | 0.020 |
Why?
|
| Standard of Care | 1 | 2013 | 564 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 1405 | 0.020 |
Why?
|
| Cisplatin | 1 | 1996 | 1662 | 0.020 |
Why?
|
| Permeability | 1 | 2011 | 738 | 0.020 |
Why?
|
| Puerto Rico | 1 | 2010 | 356 | 0.020 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 15078 | 0.020 |
Why?
|
| DNA Primers | 1 | 2014 | 2891 | 0.020 |
Why?
|
| Cross-Linking Reagents | 1 | 1992 | 694 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2018 | 4222 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2015 | 1534 | 0.020 |
Why?
|
| Zinc Fingers | 1 | 2011 | 583 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2007 | 2649 | 0.020 |
Why?
|
| DNA Methylation | 2 | 2014 | 4285 | 0.020 |
Why?
|
| Protein Methyltransferases | 1 | 2008 | 55 | 0.020 |
Why?
|
| Medical Records | 2 | 2007 | 1413 | 0.020 |
Why?
|
| Body Mass Index | 2 | 2023 | 12721 | 0.020 |
Why?
|
| Precipitin Tests | 1 | 1989 | 829 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2014 | 9735 | 0.020 |
Why?
|
| Quinolines | 1 | 2014 | 732 | 0.020 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1996 | 808 | 0.020 |
Why?
|
| Communication | 1 | 2023 | 3750 | 0.020 |
Why?
|
| Fetal Blood | 1 | 2015 | 1318 | 0.020 |
Why?
|
| Heterozygote | 1 | 2015 | 2804 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1993 | 2839 | 0.020 |
Why?
|
| Second Messenger Systems | 1 | 1989 | 206 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 1993 | 2256 | 0.020 |
Why?
|
| Age of Onset | 1 | 2015 | 3270 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 3154 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2023 | 4245 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 1504 | 0.020 |
Why?
|
| Pain | 1 | 2023 | 4988 | 0.020 |
Why?
|
| Histiocytosis, Sinus | 1 | 2008 | 47 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2002 | 2736 | 0.020 |
Why?
|
| Biological Transport | 1 | 1992 | 2120 | 0.020 |
Why?
|
| Base Pairing | 1 | 2008 | 141 | 0.020 |
Why?
|
| Imidazoles | 1 | 2014 | 1206 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2011 | 624 | 0.020 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2011 | 627 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2015 | 2740 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2021 | 6254 | 0.020 |
Why?
|
| Weight Gain | 1 | 2017 | 2293 | 0.020 |
Why?
|
| Spironolactone | 1 | 2010 | 382 | 0.020 |
Why?
|
| Insulin | 1 | 2021 | 6582 | 0.020 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 1991 | 303 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 1992 | 3130 | 0.020 |
Why?
|
| Memory | 1 | 2016 | 2174 | 0.020 |
Why?
|
| Neprilysin | 1 | 2009 | 439 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2011 | 1213 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 1997 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2002 | 4034 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2016 | 1978 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 2278 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2007 | 1375 | 0.020 |
Why?
|
| Integrases | 1 | 2008 | 533 | 0.020 |
Why?
|
| Registries | 1 | 2002 | 8091 | 0.020 |
Why?
|
| Proteome | 1 | 2016 | 1798 | 0.020 |
Why?
|
| Family Health | 1 | 2011 | 1281 | 0.020 |
Why?
|
| Attention | 1 | 2016 | 2397 | 0.020 |
Why?
|
| Sepsis | 1 | 2000 | 2593 | 0.020 |
Why?
|
| Thymopoietins | 1 | 2005 | 10 | 0.020 |
Why?
|
| Methyltransferases | 1 | 2008 | 367 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 2015 | 2073 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2008 | 894 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 5181 | 0.020 |
Why?
|
| Piperazines | 1 | 2016 | 2488 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2008 | 940 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2012 | 1683 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2010 | 1958 | 0.020 |
Why?
|
| Ganglioneuroblastoma | 1 | 1964 | 10 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 21833 | 0.020 |
Why?
|
| Prevalence | 1 | 2021 | 15221 | 0.020 |
Why?
|
| Cell Communication | 1 | 1992 | 1621 | 0.020 |
Why?
|
| Biological Availability | 1 | 2005 | 397 | 0.020 |
Why?
|
| Telemedicine | 1 | 2002 | 2872 | 0.020 |
Why?
|
| Cytoskeleton | 1 | 1989 | 1185 | 0.020 |
Why?
|
| Ganglioneuroma | 1 | 1964 | 57 | 0.020 |
Why?
|
| Ventricular Remodeling | 1 | 2012 | 1223 | 0.020 |
Why?
|
| VDJ Recombinases | 1 | 2004 | 84 | 0.010 |
Why?
|
| Half-Life | 1 | 2005 | 661 | 0.010 |
Why?
|
| Central Nervous System | 2 | 2002 | 1357 | 0.010 |
Why?
|
| Ranitidine | 1 | 2003 | 34 | 0.010 |
Why?
|
| Antipruritics | 1 | 2003 | 30 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 2009 | 1342 | 0.010 |
Why?
|
| Stem Cell Factor | 1 | 2004 | 219 | 0.010 |
Why?
|
| Carcinogenicity Tests | 1 | 2003 | 41 | 0.010 |
Why?
|
| Chromosome Breakage | 1 | 2004 | 173 | 0.010 |
Why?
|
| Diphenhydramine | 1 | 2003 | 63 | 0.010 |
Why?
|
| Catecholamines | 1 | 1964 | 387 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1989 | 3130 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2012 | 21748 | 0.010 |
Why?
|
| Chromosomes, Human, X | 1 | 2004 | 296 | 0.010 |
Why?
|
| Metabolism | 1 | 1964 | 196 | 0.010 |
Why?
|
| Annexin A5 | 1 | 2003 | 103 | 0.010 |
Why?
|
| Pharmacokinetics | 1 | 2003 | 88 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1996 | 2249 | 0.010 |
Why?
|
| Bone Marrow Examination | 1 | 2003 | 157 | 0.010 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2002 | 57 | 0.010 |
Why?
|
| Dimerization | 1 | 2004 | 895 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 3229 | 0.010 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2004 | 311 | 0.010 |
Why?
|
| Chelating Agents | 1 | 2004 | 380 | 0.010 |
Why?
|
| Protein Kinase C | 2 | 2003 | 1227 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2007 | 1586 | 0.010 |
Why?
|
| Frameshift Mutation | 1 | 2004 | 399 | 0.010 |
Why?
|
| Cyclosporins | 1 | 2002 | 220 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2015 | 5006 | 0.010 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2002 | 91 | 0.010 |
Why?
|
| Histamine H2 Antagonists | 1 | 2003 | 165 | 0.010 |
Why?
|
| Life Tables | 1 | 2002 | 370 | 0.010 |
Why?
|
| Anti-Allergic Agents | 1 | 2003 | 141 | 0.010 |
Why?
|
| Urticaria | 1 | 2003 | 150 | 0.010 |
Why?
|
| Brunner Glands | 1 | 1961 | 11 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2003 | 374 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 14723 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2003 | 367 | 0.010 |
Why?
|
| Sex Factors | 1 | 2016 | 10400 | 0.010 |
Why?
|
| Interleukin-3 | 1 | 2003 | 444 | 0.010 |
Why?
|
| Computer Systems | 1 | 2003 | 483 | 0.010 |
Why?
|
| Norepinephrine | 1 | 1964 | 909 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2003 | 876 | 0.010 |
Why?
|
| Data Collection | 1 | 2011 | 3339 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2003 | 772 | 0.010 |
Why?
|
| Patient Selection | 1 | 2013 | 4216 | 0.010 |
Why?
|
| Antigen-Presenting Cells | 1 | 2005 | 973 | 0.010 |
Why?
|
| Pathology | 1 | 1964 | 272 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2003 | 535 | 0.010 |
Why?
|
| Obesity | 1 | 2023 | 12746 | 0.010 |
Why?
|
| RNA, Viral | 1 | 1989 | 2901 | 0.010 |
Why?
|
| Endopeptidases | 1 | 2004 | 772 | 0.010 |
Why?
|
| Epinephrine | 1 | 1964 | 792 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2005 | 1655 | 0.010 |
Why?
|
| Adenomatous Polyps | 1 | 1961 | 107 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 2004 | 1005 | 0.010 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2004 | 584 | 0.010 |
Why?
|
| Drug Eruptions | 1 | 2003 | 297 | 0.010 |
Why?
|
| Genes, Homeobox | 1 | 2001 | 286 | 0.010 |
Why?
|
| Protease Inhibitors | 1 | 2004 | 791 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 1996 | 4251 | 0.010 |
Why?
|
| Endothelial Growth Factors | 1 | 2003 | 694 | 0.010 |
Why?
|
| Genetic Heterogeneity | 1 | 2004 | 733 | 0.010 |
Why?
|
| Pruritus | 1 | 2003 | 361 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2012 | 3778 | 0.010 |
Why?
|
| Polyps | 1 | 1961 | 189 | 0.010 |
Why?
|
| Lymphokines | 1 | 2003 | 949 | 0.010 |
Why?
|
| Monocytes | 1 | 1989 | 2596 | 0.010 |
Why?
|
| Nausea | 1 | 2002 | 674 | 0.010 |
Why?
|
| Point Mutation | 1 | 2004 | 1624 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 19905 | 0.010 |
Why?
|
| Cell Differentiation | 2 | 2008 | 11486 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2001 | 769 | 0.010 |
Why?
|
| Necrosis | 1 | 2003 | 1643 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 2002 | 498 | 0.010 |
Why?
|
| Duodenum | 1 | 1961 | 484 | 0.010 |
Why?
|
| Leucovorin | 1 | 2000 | 628 | 0.010 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2000 | 232 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2014 | 3751 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 3848 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2007 | 3493 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2010 | 5984 | 0.010 |
Why?
|
| Dopamine | 1 | 1964 | 1591 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 3001 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 1964 | 1226 | 0.010 |
Why?
|
| Europe | 1 | 2003 | 3338 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 2002 | 1423 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2004 | 2967 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 3508 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2003 | 1677 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 18034 | 0.010 |
Why?
|
| Cell Line | 1 | 1989 | 16000 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 4839 | 0.010 |
Why?
|
| Transfection | 1 | 2003 | 5895 | 0.010 |
Why?
|
| Enzyme Activation | 2 | 1992 | 3702 | 0.010 |
Why?
|
| Vinblastine | 1 | 1996 | 502 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 12961 | 0.010 |
Why?
|
| Mortality | 1 | 2005 | 2864 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 2011 | 5181 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2002 | 2133 | 0.010 |
Why?
|
| Educational Measurement | 1 | 2000 | 1210 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2001 | 1928 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 2000 | 1403 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 1992 | 116 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2003 | 3511 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 8861 | 0.010 |
Why?
|
| Type C Phospholipases | 1 | 1992 | 292 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 1991 | 5692 | 0.010 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 1992 | 294 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1992 | 573 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 15535 | 0.010 |
Why?
|
| Zidovudine | 1 | 1992 | 620 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1996 | 1842 | 0.010 |
Why?
|
| Ionomycin | 1 | 1989 | 109 | 0.010 |
Why?
|
| Ethers | 1 | 1989 | 75 | 0.010 |
Why?
|
| Logistic Models | 1 | 2004 | 13409 | 0.010 |
Why?
|
| Mitogens | 1 | 1989 | 232 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 35425 | 0.000 |
Why?
|
| Hydrolysis | 1 | 1989 | 682 | 0.000 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1992 | 805 | 0.000 |
Why?
|
| Cholecalciferol | 1 | 1992 | 535 | 0.000 |
Why?
|
| Isoenzymes | 1 | 1992 | 1728 | 0.000 |
Why?
|
| Flowmeters | 1 | 1946 | 6 | 0.000 |
Why?
|
| Vital Capacity | 1 | 1946 | 925 | 0.000 |
Why?
|
| Cell Division | 1 | 1989 | 4569 | 0.000 |
Why?
|
| Neoplasm Metastasis | 1 | 1991 | 4851 | 0.000 |
Why?
|
| Kidney | 1 | 1996 | 7184 | 0.000 |
Why?
|
| Stem Cells | 1 | 1992 | 3567 | 0.000 |
Why?
|